17,261 trials
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival (PFS) at 6 Months — 25; 7.7 percentage of participants
Colorectal Cancer
Primary: Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases — 42.2 percentage of participants
Hyperlipidemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 2.76; -0.98; -39.06; -57.48 percent change — p=<0.001
Gastric Cancer
Primary: Percentage of Participants With Disease-free Survival (DFS) at Month 18 — 76.12 percentage of participants
Cirrhosis · Hepatic Encephalopathy
Primary: Part A: The Rate of AEs and Tolerability of HPN-100 — 11; 9; 7; 4 Subjects
Endometrial Cancer
Primary: Percentage of Women With Advanced or Recurrent Endometrial Cancer Who Have Neither Progressed Nor Died — 36.1; 54.1 Percentage of subjects
Tourette's Syndrome
Primary: Yale Global Tic Severity Score — 25.3 units on a scale
Psychotic Disorders · Bipolar Disorder · Unemployment
Primary: Participation in Vocational Rehabilitation Services — 19; 3 participants — p=<0.001
Hypercholesterolemia, Familial
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 1.12; -42.70; -55.24 percent change — p=<0.001
Pharmacokinetics · Renal Impaired · Healthy Volunteer
Primary: Time to Reach Maximum Peak Plasma Concentration (Tmax) After Single Dose (Day 1), and After Multiple Dose Administration (Day 5) — 0.5; 0.5; 0.5; 0.5 hour
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks — -1.35; -1.15; -0.90; -0.18 percentage glycosylated hemoglobin — p=<.001
Mild to Moderate Hypertension
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCtau) of LCZ696 Analytes — 3700; 147000; 23600 h*ng/mL
Prolonged QT Interval in EKG and Sudden Death
Primary: Baseline (Pre-Ibutilide) QTcI Intervals — 412; 419 ms — p=0.04
Systemic Sclerosis
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) — 96.9; 96.8 percentage of participants
Stage II Gallbladder Cancer · Stage IIIA Gallbladder Cancer · Stage IIIB Gallbladder Cancer
Primary: Response Rate According to RECIST Criteria — 3; 0 participants